Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies: Part 2: Imatinib Resistance and Other Diseases Targeted by Imatinib (25:12)

March 11, 2009
2583 views
URL
Embed
Share

Please describe the reason for abuse:



Description:
Although the majority of patients with CML respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover... » More

Belongs to: